Press release
The "RNAi Therapeutics and Technologies Market" report features an extensive study of the current market landscape and the likely future potential; associated with the RNAi therapeutics market, over the next decade
1. A detailed overview of the overall market landscape of players engaged in the development of RNAi therapeutics, based on several relevant parameters, such as phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, target disease indication(s), key therapeutic areas (oncological disorders, infectious diseases, genetic disorders, ophthalmic diseases, respiratory disorders, hepatic disorders, metabolic disorders, cardiovascular disorders, dermatological disorders and other disorders), type of RNAi molecule (siRNA, miRNA, shRNA, sshRNA and DNA), target gene, route of administration and special drug designations (if any).
2. A detailed overview of the players engaged in the development of RNAi therapeutics, based on several relevant parameters, such as year of establishment, company size, location of headquarters and regional landscape.
3. A competitiveness analysis of RNAi therapeutic developers, based on developer strength (in terms of employee count and years of experience) and product portfolio strength (in terms of number of RNAi molecules across different phases of development, type of RNAi molecule offered, purpose of technology and target therapeutic area).
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/rnai-therapeutics-market-2nd-edition-2019-2030/request-quote.html
4. Elaborate profiles of drug candidates that are in the advanced stages of development (phase II / III and above). Each drug profile features information on the current development status of the drug, along with details on its developer, mechanism of action, route of administration, affiliated technology Platform (if available), dosage and recent clinical trial results.
5. An overview of the current market landscape of technology platforms available for the development of RNAi therapeutics, along with information on their developer, purpose of technology, type of molecule (s) delivered and type of cell (s) / tissue (s) targeted. In addition, the chapter includes information on technology developer(s), highlighting the year of their establishment, company size and location of headquarters. The chapter also includes brief profiles of key RNAi-based drug discovery / development technology platforms and drug delivery technologies (shortlisted on the basis of competitiveness score). Each profile features details on the various pipeline molecules that have been / are being developed using the technology and insights from patents associated with the technology.
6. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
7. A detailed analysis of the target indications (segregated by various therapeutic areas, including oncological disorders, infectious diseases, metabolic disorders, ophthalmic diseases and genetic disorders) that are currently the prime focus of companies engaged in the development of RNAi therapeutics.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/rnai-therapeutics-market-2nd-edition-2019-2030/request-sample.html
8. An analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, current status, phase of development, type of RNAi molecule, enrolled patient population and regional distribution of trials.
9. An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field.
10. An in-depth analysis of patents related to RNAi therapeutics, filed / granted, since 2016, based on type of patent (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.
11. A detailed review of around 3,000 peer-reviewed, scientific articles related to research on RNAi therapeutics, based on several relevant parameters, such as year of publication, type of publication, popular keywords, top journals, top publishers, key copyright holders and key funding institutes.
12. An analysis of the various partnerships related to RNAi therapeutics inked by players engaged in this domain, based on various parameters, such as the type of partnership, year of partnership, target disease indication, therapeutic area, type of RNAi molecule, financial details (wherever applicable), focus area of collaboration and most active players (in terms of number of partnerships).
13. A detailed analysis of various investments made by players engaged in this domain, during the period 2016-2021, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings), amount invested, type of RNAi molecule, most active players (in terms of number and amount of funding instances) and key investors (in terms of number of instances).
14. An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug.
15. An elaborate discussion on the use of miRNA as a potential biomarker, along with a list of diagnostic kits that are either available in the market, or likely to be approved in the foreseen future.
16. A detailed analysis of the companies that are actively supporting the development of RNAi therapeutics market, including contract manufacturers, contract researcher organizations and other service providers based on various parameters, such as type of service provider, location of their headquarters and type of RNAi molecule developed.
17. An informed estimate of the annual clinical and commercial demand for RNAi therapeutics, taking into account the target patient population in ongoing and planned clinical trials of RNAi therapeutics, sponsored by both industry and non-industry players.
18. A detailed analysis capturing affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the RNAi therapeutics market.
19. Informed estimates on the evolution of the market for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Key Therapeutic Areas
1. Oncological Disorders
2. Genetic Disorders
3. Metabolic Disorders
4. Hematological Disorders
5. Ophthalmic Disorders
6. Others
Routes of Administration
1. Subcutaneous
2. Intravenous
3. Topical
4. Intradermal
Types of RNAi Molecules
1. siRNA
2. shRNA
Key Geographical Regions
1. North America
2. Europe
3. Asia-Pacific and the Rest of the World
Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/rnai-therapeutics-market/278.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The "RNAi Therapeutics and Technologies Market" report features an extensive study of the current market landscape and the likely future potential; associated with the RNAi therapeutics market, over the next decade here
News-ID: 3942881 • Views: …
More Releases from Roots Analysis
AAV vector market is anticipated to reach to USD 6.0 billion by 2035 with CAGR o …
Adeno-associated virus (AAV) vectors have emerged as one of the most promising tools for gene delivery in both basic research and clinical gene therapy. Derived from the non-pathogenic AAV, these vectors offer several advantages, including low immunogenicity, the ability to infect both dividing and non-dividing cells, and long-term transgene expression in a variety of tissues.
The global AAV vector market estimated to grow from USD 2.2 billion in 2024 to 3.6…
Continuous Manufacturing Market is Set to Soar to USD 4,193 Million by 2035 with …
Advances in manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step batch manufacturing processes to faster, and relatively more efficient continuous manufacturing
The continuous manufacturing market valued at USD 2,349 million in 2024, is project to reach USD 2,599 million in 2025 and USD 4,193 million by 2035, representing a CAGR of 4.9% during the forecast period 2025 to 2035.
For decades, pharmaceutical companies have been using batch…
Respiratory syncytial virus infections are recognized among the prevalent respir …
Currently, several traditional techniques are available for treating these infections, although none of them have been competent enough to reduce the healthcare burden of RSV diseases. In order to address this, RSV vaccines emerged as a promising alternative, which provides active immunity against the RSV infections, thus protecting the vulnerable population. Further, by providing targeted immunity, these vaccines help reducing the severity of RSV infections and lower the hospitalization rates…
Rise in demand of glp-1 drugs for metabolic disorders.
In recent years, owing to its broader clinical potential in the treatment of obesity and type 2 diabetes, along with their proven efficacy in reducing cardiovascular risks, GLP-1 drugs market has garnered significant traction within the medical science domain.
Concurrently, the rising demand and escalating prevalence of metabolic disorder including type 2 diabetes and obesity are fueling the need for treatments capable of effectively managing these conditions. This trend is expected…
More Releases for RNAi
RNAi Technology Market to see Booming Business Sentiments
The latest study released on the Global RNAi Technology Market by USD Analytics Research evaluates market size, trend, and forecast to 2030. The RNAi Technology market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key Players…
RNAi Technology Market to see Booming Business Sentiments
The "Global RNAi Technology" intelligence report, just published by USD Analytics, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Global RNAi Technology provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study…
Global RNAi Drug Pipeline Analysis
“Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. Research report covers all the ongoing drugs being developed in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each drug profile in…
Global RNA Interference (RNAi) Therapy Market Outlook 2018
The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry.
Since discovery, RNA interference is considered to be a turning…
Global RNAI Interfering System Market Research Report 2017
Summary
RNAI Interfering System Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
The report firstly introduced the RNAI Interfering System basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes;…
Global RNAI Vector Market Research Report 2017
Summary
RNAI Vector Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
The report firstly introduced the RNAI Vector basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures,…
